Osteoporosis

>

Latest News

Biosimilars to Denosumab Win FDA Approval as Amgen and Sandoz Go to Court / image credit osteoporosis progression: ©crevis/stock.adobe.com
Two Biosimilars to Denosumab Win FDA Approval as Amgen and Sandoz Go to Court

March 6th 2024

Biosimilars Wyost and Jubobonti were approved as interchangeable for Xgeva and Prolia but launch will depend on the outcome of litigation between reference product manufacturers.

Daily Dose: Lack of Osteoporosis Screening, Treatment in Patients with Cirrhosis / image credit: ©New Africa/AdobeStock
Daily Dose: Lack of Osteoporosis Screening, Treatment in Patients with Cirrhosis

January 19th 2024

Screening and Treatment for Osteoporosis Lacking in Patients with Cirrhosis, According to Real-World Analysis / Image credit: ©RFBSIP/AdobeStock
Screening and Treatment for Osteoporosis Lacking for Persons with Cirrhosis, According to Real-World Analysis

January 12th 2024

Fracture risk reduction greater with denosumab vs alendronate osteoporotic femur image © Crevis/Adobe Stock
Denosumab Superior to Alendronate for Reduction of Postmenopausal Fracture Risk in Real-world Study

May 10th 2023

Weekly primary care research update
Friday's 5 Quotes for Primary Care 5-5-2023

May 5th 2023

More News

© 2024 MJH Life Sciences

All rights reserved.